Beyond Yield: Assessing AAV Vector Quality Across Process Development
As gene therapy development advances, understanding viral vector quality is becoming just as important as measuring yield. For recombinant adeno-associated virus (rAAV) programs, a key challenge is determining whether vectors contain full-length therapeutic genomes or truncated and partial genome fragments.
Established methods such as ELISA, ddPCR, and analytical ultracentrifugation (AUC) each provide valuable insights, but no single approach captures every aspect of vector quality across process development and manufacturing.
This webinar will examine how complementary and emerging analytical approaches can provide a more complete picture of rAAV yield, genome integrity, and full-particle content.
Join us to learn:
Why full-length genome encapsidation matters when assessing rAAV vector quality
What ELISA, ddPCR, and AUC can—and cannot—reveal about vector characterization
How emerging nanoneedle approaches may expand analysis across clarified harvest and purified samples
How combining analytical methods can inform process development, characterization, and optimization
Speakers
